The preclinical candidate indole-2-carboxamide improves immune responses to Mycobacterium tuberculosis infection in healthy subjects and individuals with type 2 diabetes

Ruoqiong Cao, Hicret Islamoglu, Garrett Teskey, Karo Gyurjian, Rachel Abrahem, Oluseye K. Onajole, Shichun Lun, William Ramses Bishai, Alan P. Kozikowski, Marcel P. Fraix, Airani Sathananthan, Li Zhong, Jozef Stec, Vishwanath Venketaraman

Research output: Contribution to journalArticle

Abstract

A novel group of agents known as the indole-2-carboxamides (often referred to as indoleamides) have been shown to demonstrate high antimycobacterial activity. Studies have demonstrated that the best indoleamides possess desirable ADME/Tox properties, with less adverse effects and increased efficacy against both MDR-TB (multi-drug resistant TB) and XDR-TB (extensively drug-resistant TB). The primary mechanism of killing Mycobacterium tuberculosis (Mtb) by indoleamides is by disrupting the function of the essential mycolic acid transporter MmpL3 protein (Mycobacterial membrane protein Large 3). Therefore, targeting this essential mycobacterial transporter by small molecules opens new possibility for the development of novel and effective anti-TB agents. In the present study, we characterized the effects of indoleamides in altering the viability of Mtb in an in vitro granuloma model using immune cells derived from healthy subjects and those with type 2 diabetes mellitus (T2DM). Our results indicate that treatment with the best indoleamide 3 resulted in a significant reduction in the viability of Mtb in both THP-1 macrophages as well as in granulomas derived from healthy individuals and subjects with T2DM. [Figure not available: see fulltext.].

Original languageEnglish (US)
JournalInternational Microbiology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Mycobacterium Infections
Mycobacterium tuberculosis
Type 2 Diabetes Mellitus
Healthy Volunteers
Granuloma
Extensively Drug-Resistant Tuberculosis
Mycolic Acids
Pharmaceutical Preparations
Membrane Proteins
Macrophages
indole
Proteins
Therapeutics

Keywords

  • Cytokines
  • Drug discovery
  • Infection immunity
  • Innate immunity
  • Intracellular parasitology
  • Mycobacterium tuberculosis

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

The preclinical candidate indole-2-carboxamide improves immune responses to Mycobacterium tuberculosis infection in healthy subjects and individuals with type 2 diabetes. / Cao, Ruoqiong; Islamoglu, Hicret; Teskey, Garrett; Gyurjian, Karo; Abrahem, Rachel; Onajole, Oluseye K.; Lun, Shichun; Bishai, William Ramses; Kozikowski, Alan P.; Fraix, Marcel P.; Sathananthan, Airani; Zhong, Li; Stec, Jozef; Venketaraman, Vishwanath.

In: International Microbiology, 01.01.2019.

Research output: Contribution to journalArticle

Cao, Ruoqiong ; Islamoglu, Hicret ; Teskey, Garrett ; Gyurjian, Karo ; Abrahem, Rachel ; Onajole, Oluseye K. ; Lun, Shichun ; Bishai, William Ramses ; Kozikowski, Alan P. ; Fraix, Marcel P. ; Sathananthan, Airani ; Zhong, Li ; Stec, Jozef ; Venketaraman, Vishwanath. / The preclinical candidate indole-2-carboxamide improves immune responses to Mycobacterium tuberculosis infection in healthy subjects and individuals with type 2 diabetes. In: International Microbiology. 2019.
@article{a35b742523764c84afac270c4bfdb73b,
title = "The preclinical candidate indole-2-carboxamide improves immune responses to Mycobacterium tuberculosis infection in healthy subjects and individuals with type 2 diabetes",
abstract = "A novel group of agents known as the indole-2-carboxamides (often referred to as indoleamides) have been shown to demonstrate high antimycobacterial activity. Studies have demonstrated that the best indoleamides possess desirable ADME/Tox properties, with less adverse effects and increased efficacy against both MDR-TB (multi-drug resistant TB) and XDR-TB (extensively drug-resistant TB). The primary mechanism of killing Mycobacterium tuberculosis (Mtb) by indoleamides is by disrupting the function of the essential mycolic acid transporter MmpL3 protein (Mycobacterial membrane protein Large 3). Therefore, targeting this essential mycobacterial transporter by small molecules opens new possibility for the development of novel and effective anti-TB agents. In the present study, we characterized the effects of indoleamides in altering the viability of Mtb in an in vitro granuloma model using immune cells derived from healthy subjects and those with type 2 diabetes mellitus (T2DM). Our results indicate that treatment with the best indoleamide 3 resulted in a significant reduction in the viability of Mtb in both THP-1 macrophages as well as in granulomas derived from healthy individuals and subjects with T2DM. [Figure not available: see fulltext.].",
keywords = "Cytokines, Drug discovery, Infection immunity, Innate immunity, Intracellular parasitology, Mycobacterium tuberculosis",
author = "Ruoqiong Cao and Hicret Islamoglu and Garrett Teskey and Karo Gyurjian and Rachel Abrahem and Onajole, {Oluseye K.} and Shichun Lun and Bishai, {William Ramses} and Kozikowski, {Alan P.} and Fraix, {Marcel P.} and Airani Sathananthan and Li Zhong and Jozef Stec and Vishwanath Venketaraman",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10123-019-00086-0",
language = "English (US)",
journal = "International Microbiology",
issn = "1139-6709",
publisher = "Sociedad Espanola de Microbiologia",

}

TY - JOUR

T1 - The preclinical candidate indole-2-carboxamide improves immune responses to Mycobacterium tuberculosis infection in healthy subjects and individuals with type 2 diabetes

AU - Cao, Ruoqiong

AU - Islamoglu, Hicret

AU - Teskey, Garrett

AU - Gyurjian, Karo

AU - Abrahem, Rachel

AU - Onajole, Oluseye K.

AU - Lun, Shichun

AU - Bishai, William Ramses

AU - Kozikowski, Alan P.

AU - Fraix, Marcel P.

AU - Sathananthan, Airani

AU - Zhong, Li

AU - Stec, Jozef

AU - Venketaraman, Vishwanath

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A novel group of agents known as the indole-2-carboxamides (often referred to as indoleamides) have been shown to demonstrate high antimycobacterial activity. Studies have demonstrated that the best indoleamides possess desirable ADME/Tox properties, with less adverse effects and increased efficacy against both MDR-TB (multi-drug resistant TB) and XDR-TB (extensively drug-resistant TB). The primary mechanism of killing Mycobacterium tuberculosis (Mtb) by indoleamides is by disrupting the function of the essential mycolic acid transporter MmpL3 protein (Mycobacterial membrane protein Large 3). Therefore, targeting this essential mycobacterial transporter by small molecules opens new possibility for the development of novel and effective anti-TB agents. In the present study, we characterized the effects of indoleamides in altering the viability of Mtb in an in vitro granuloma model using immune cells derived from healthy subjects and those with type 2 diabetes mellitus (T2DM). Our results indicate that treatment with the best indoleamide 3 resulted in a significant reduction in the viability of Mtb in both THP-1 macrophages as well as in granulomas derived from healthy individuals and subjects with T2DM. [Figure not available: see fulltext.].

AB - A novel group of agents known as the indole-2-carboxamides (often referred to as indoleamides) have been shown to demonstrate high antimycobacterial activity. Studies have demonstrated that the best indoleamides possess desirable ADME/Tox properties, with less adverse effects and increased efficacy against both MDR-TB (multi-drug resistant TB) and XDR-TB (extensively drug-resistant TB). The primary mechanism of killing Mycobacterium tuberculosis (Mtb) by indoleamides is by disrupting the function of the essential mycolic acid transporter MmpL3 protein (Mycobacterial membrane protein Large 3). Therefore, targeting this essential mycobacterial transporter by small molecules opens new possibility for the development of novel and effective anti-TB agents. In the present study, we characterized the effects of indoleamides in altering the viability of Mtb in an in vitro granuloma model using immune cells derived from healthy subjects and those with type 2 diabetes mellitus (T2DM). Our results indicate that treatment with the best indoleamide 3 resulted in a significant reduction in the viability of Mtb in both THP-1 macrophages as well as in granulomas derived from healthy individuals and subjects with T2DM. [Figure not available: see fulltext.].

KW - Cytokines

KW - Drug discovery

KW - Infection immunity

KW - Innate immunity

KW - Intracellular parasitology

KW - Mycobacterium tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85067802487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067802487&partnerID=8YFLogxK

U2 - 10.1007/s10123-019-00086-0

DO - 10.1007/s10123-019-00086-0

M3 - Article

C2 - 31218537

AN - SCOPUS:85067802487

JO - International Microbiology

JF - International Microbiology

SN - 1139-6709

ER -